Zydus Lifesciences Directed to Revise PMS Study for Tofacitinib ER Tablets
Zydus Lifesciences Ltd. has been directed by the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) to revise its Post-Marketing Surveillance (PMS) study protocol for Tofacitinib Extended-Release Tablets 11 mg.
This decision follows a detailed review during the committee meeting held on September 17, 2025, at CDSCO headquarters in New Delhi, where the firm presented its proposal seeking permission to conduct an Active Post-Marketing Surveillance (PMS) study for Tofacitinib Extended-Release Tablets 11 mg, vide protocol No. C2B05724.
After thorough evaluation, the SEC reviewed the study design and recommended a series of changes to strengthen the protocol’s clinical robustness and safety monitoring parameters.
Author's summary: Zydus Lifesciences must revise PMS study.
More News
- Founding partner Microsoft to bring new Discovery AI technology to NJ AI Hub
- Fashion lovers step out for Carol Byrne X Very Partywear Edit
- Election Guide 2025: Nassau County Legislature District 7 candidate Alec Fischthal, Dem.
- Genesis to acquire 271MWp Waikato solar project in New Zealand
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Uzbekistan, Slovakia seek to break new ground in trade and digital collaboration
- “He Left His Mark on the Hands of Time”
- Asim Qureshi · Short Cuts: Misuses of the Terrorism Act
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Dutch election: D66 and PVV neck and neck with smallest difference ever